Suppression of erosive arthritis by NF-κB inhibitors

Current Rheumatology Reviews

Volumn 7, Issue 4, 2011, Pages 275-281

  Kubota, Tetsuo ^a   Umezawa, Kazuo ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Chemotherapy; DHMEQ; Macrophage; NF kappa B; NFATc1; Osteoclast

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; CORTICOSTEROID; DEHYDROXYMETHYLEPOXYQUINOMICIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 1BETA; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGODEOXYNUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROSIS; CACHEXIA; CANCER INHIBITION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; GENE THERAPY; GENETIC RISK; GRAFT REJECTION; HUMAN; INHIBITION KINETICS; NEOPLASM; NEPHRITIS; NONHUMAN; ORGAN INJURY; OSTEOCLASTOGENESIS; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; RETINITIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

EID: 82155192972     PISSN: 15733971     EISSN: 18756360     Source Type: Journal    
DOI: 10.2174/157339711798221077     Document Type: Article

References (39)

1. Gorman JD, Lum RF, Chen JJ, Suarez-Almazor ME, Thomson G, Criswell LA. Impact of shared epitope genotype and ethnicity on erosive disease. A meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 400-12.
2. van der Woude D, Houwing-Duistermaat JJ, et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-nagative rheumatoid arthritis. Arthritis Rheum 2009; 60: 916-23.
3. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis. Smoking may trigger HLA-DR (sharedepitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54: 38-46.
4. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
5. Smolen JS, van der Heijde DMFM, St.Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702-10.
6. Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.
7. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κB in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995; 38: 1762-70.
8. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996; 39: 583-91.
9. Benito MJ, Murphy E, Murphy EP, van den Berg WB, FitzGerald O, Bresnihan B. Increased synovial tissue NF-κB1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1781-7.
10. Fujisawa K, Aono H, Hasunuma T, Yamamoto K, Mita S, Nishioka K. Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α. Arthritis Rheum 1996; 39: 197-203.
11. Aupperle KR, Bennett BL, Han Z, Boyle DL, Manning AM, Firestein GS. NF-κB regulation by IκB kinase-2 in rheumatoid arthritis synoviocytes. J Immunol 2001; 166: 2705-11.
12. Erkel G, Anke T, Sterner O. Inhibition of NF-κB activation by panepoxydone. Biochem Biophys Res Commun 1996; 226: 214-221.
13. Gehrt A, Erkel, G, Anke, T, SternerO.Cycloepoxydon,1-hydroxy-2-hydroxymethyl-3-pent-1-enylbenzene 1-hydroxy-2-hydroxy-methyl-3-pent-1, 3-dienylbenzene, new inhibitors of eukaryotic signal transduction. J Antibiot 1998; 51: 455-63.
14. Matsumoto N, Ariga A, To-e S, et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000; 10: 865-9.
15. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of TNF-α-induced nuclear translocation and activation of NF-κB by dehydroxymethyl-epoxyquinomicin. J Biol Chem 2002; 277: 27625-30.
16. Suzuki Y, Sugiyama C, Ohno O, Umezawa K. Preparation and biological activities of optically active dehydroxymethylepoxy-quinomicin, a novel NF-κB inhibitor. Tetrahedron 2004; 60: 7061-6.
17. Umezawa K. Inhibition of tumor growth by NF-κB inhibitors. Cancer Sci 2006; 97: 990-5.
18. Chiba T, Kondo Y, Shinozaki S, et al. A selective NF-κB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. J Atheroscler Thromb 2006; 13: 308-13.
19. Nagai N, Oike Y, Izumi-Nagai K, et al. Suppression of diabetes induced retinal inflammation by blocking angiotensin II type 1 receptor or its downstream NF-κB pathway. Invest Ophthal Vis Sci 2007; 48: 4342-50.
20. Ueki S, Yamashita K, Aoyagi T, et al. Control of allograft rejection by applying a novel NF-κB inhibitor, dehydroxymethyl-epoxyquinomicin. Transplantation 2006; 82: 1720-7.
21. Suzuki T, Yamashita K, Jomen W, et al.The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. J Surg Res 2008; 149: 69-75.
22. Watanabe M, Dewan MZ, Taira M, et al. IκBα independent induction of NF-κB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. Lab Invest 2007; 87: 372-82.
23. Matsumoto G, Muta M, Umezawa K, et al. Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF-κB inhibitor. Int J Oncology 2005; 27: 1247-55.
24. Miyake A, Dewan Z, Ishida T, et al. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-κB inhibitor DHMEQ. Microbes Infect 2008; 10: 748-56.
25. Yamamoto M, Horie R, Takeiri M, Kozawa I, Umezawa K. Inactivation of nuclear factor kappa B components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. J Med Chem 2008; 51: 5780-8.
26. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998; 28: 197-208.
27. Tak PP, Gerlag DM, Aupperle KR, et al. Inhibitor of nuclear factor κB kinase β is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897-907.
28. Miagkov AV, Kovalenko DV, Brown CE, et al. NF-κB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 1998; 95: 13859-64.
29. Tomita T, Takeuchi E, Tomita N, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor κB decoy oligodeoxynucleotides as a gene therapy. Arthtitis Rheum 1999; 42: 2532-42.
30. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-6.
31. McIntyre KW, Shuster DJ, Gillooly KM, et al. A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003; 48: 2652-9.
32. Gerlag DM, Ransone L, Tak PP, et al. The effect of a T cell-specific NF-κB inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000; 165: 1652-8.
33. Aramaki T, Kawakami A, Iwamoto N, et al. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. Mod Rheumatol 2009; 19: 652-6.
34. Korhonen R, Moilanen E. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. Basic Clin Pharmacol Toxicol 2009; 104: 276-84.
35. Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T. Effect of a small molecule inhibitor of nuclear factor-κB nuclear translocation in a murine model of arthritis and cultured human synovial cells. Arthritis Res Ther 2005; 7: R1348-59.
36. Takatsuna H, Asagiri M, Kubota T, et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1. J Bone Miner Res 2005; 20: 653-62.
37. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83:170-9.
38. Kubota T, Hoshino M, Aoki K, et al. NF-κB inhibitor dehydroxymethylepoxyquinomicin suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANKL, osteoprotegerin or macrophage colony-stimulating factor. Arthritis Res Ther 2007;9:R97.
39. Jimi E, Aoki K, Saito H, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004; 10: 617-24.